You are here

Generic Oxycontin Now Available

Jerusalem, Israel, March 30, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that subsequent to the approval of its ANDA dated March 24, 2004, the U.S. Food and Drug Administration now regards the Company's voluntary risk management program (RMP) for Oxycodone Hydrochloride Extended Release Tablets, 80 mg as operational. As a result, Teva is commencing the initial commercialization of the product.

Oxycodone Hydrochloride ER Tablets are the AB-rated generic equivalent of Purdue Pharma's OxyContin® Controlled Release Tablets, 80 mg. This product is indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time.

Source: Teva Pharmaceutical Industries Ltd.

Recent Headlines

Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs